An investigation was announced for investors in NASDAQ:MCRB shares concerning potential breaches of fiduciary duties by certain directors of Seres Therapeutics.
Investors who are current long term investors in Seres Therapeutics Inc (NASDAQ:MCRB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm for in NASDAQ:MCRB stocks follows a lawsuit filed recently against Seres Therapeutics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:MCRB stocks, concerns whether certain Seres Therapeutics directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that the defendants made certain materially false and misleading positive statements about the potential and efficacy of its lead drug product candidate SER-109. In particular, the plaintiff alleges that Seres Therapeutics Inc touted the drug, calling it one among a “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo.
Those who purchased NASDAQ:MCRB shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments